a9675t
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Notice of Annual General Meeting
30 March 2021 12:15 BST
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2021 and Shareholders'
Circular (the Notice).
The Notice has been submitted to the National Storage Mechanism and
will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website
at www.astrazeneca.com/noticeofmeeting2021
The Company's Annual Report and Form 20-F Information 2020 (the
Annual Report) was published on 15 February 2021.
The Notice is being despatched to shareholders today.
The date of the 2021 Annual General Meeting of the Company (the
AGM) has been changed since the publication of the Annual Report,
which indicated the AGM would take place on 30 April 2021. The
AGM will now be held on Tuesday 11 May 2021 at 11.00am (BST)
at Academy House, 136 Hills Road, Cambridge CB2 8PA. In line with
UK Government restrictions relating to public gatherings as at the
date of the Notice, the AGM will be a closed meeting and it will
not be possible for shareholders to attend.
Shareholders are strongly encouraged to vote in advance of the
meeting by appointing the Chairman of the AGM as their proxy. This
means the Chairman of the AGM will be able to vote on their behalf,
and in accordance with their instructions, at the AGM. Further
details on how shareholders can appoint the Chairman of the AGM as
their proxy can be found on page 10 of the
Notice.
The Board values the support and engagement of all shareholders. On
Friday 30 April 2021 at 2.00pm (BST), the Company will
live-broadcast online a presentation from certain members of the
Board and invite shareholders to participate in a live Q&A
session should they wish to do so. Details about how to access the
shareholder engagement event, and how to ask questions can be found
from page 12 of the Notice.
In respect of the proposed acquisition of Alexion Pharmaceuticals
Inc. (the Transaction), a separate Notice of Meeting and
Shareholders' Circular will be published and despatched to
shareholders in due course in connection with the shareholders'
general meeting at which approval to proceed with the Transaction
will be sought.
The Company continues to monitor the situation in relation to
COVID-19 and will notify shareholders via our
website, www.astrazeneca.com as
soon as practicably possible if there are any changes to the AGM
arrangements.
The business to be conducted at the AGM is summarised
below:
1.
To receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December
2020
2.
To confirm dividends
3.
To reappoint PricewaterhouseCoopers LLP as Auditor
4.
To authorise the Directors to agree the remuneration of the
Auditor
5.
To elect or re-elect Directors
6.
To approve the Annual Report on Remuneration for the year ended 31
December 2020
7.
To approve the Directors' Remuneration Policy
8.
To authorise limited political donations
9.
To authorise the Directors to allot shares
10.
To authorise the Directors to disapply pre-emption
rights
11.
To authorise the Directors to further disapply pre-emption rights
for acquisitions and specified capital investments
12.
To authorise the Company to purchase its own shares
13.
To reduce the notice period for general meetings
14.
To amend the rules of the Performance Share Plan 2020
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three therapy
areas - Oncology, Cardiovascular, Renal & Metabolism, and
Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
30 March
2021
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|